Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

MLA

Salazar, Ramon, et al. “Phase 1 Dose Escalation and Pharmacokinetic Evaluation of Oral Gemcitabine Prodrug (LY2334737) in Combination with Docetaxel in Patients with Advanced Solid Tumors.” Cancer Chemotherapy and Pharmacology, vol. 73, no. 6, June 2014, pp. 1205–15. EBSCOhost, https://doi.org/10.1007/s00280-014-2457-1.

APA

Salazar, R., Morales, S., Gil-Martín, M., Aguirre, E., Oaknin, A., Garcia, M., Callies, S., Wickremsinhe, E. R., Benhadji, K. A., & Llombart, A. (2014). Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 73(6), 1205–1215. https://doi.org/10.1007/s00280-014-2457-1

Chicago

Salazar, Ramon, Serafin Morales, Marta Gil-Martín, Elena Aguirre, Ana Oaknin, Margarita Garcia, Sophie Callies, Enaksha R Wickremsinhe, Karim A Benhadji, and Antonio Llombart. 2014. “Phase 1 Dose Escalation and Pharmacokinetic Evaluation of Oral Gemcitabine Prodrug (LY2334737) in Combination with Docetaxel in Patients with Advanced Solid Tumors.” Cancer Chemotherapy and Pharmacology 73 (6): 1205–15. doi:10.1007/s00280-014-2457-1.